<DOC>
	<DOCNO>NCT00054626</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know combination chemotherapy effective preventing relapse patient undergone radical cystectomy bladder cancer . PURPOSE : Phase III trial compare effectiveness cisplatin combine gemcitabine observation treat patient bladder cancer undergone surgery remove bladder .</brief_summary>
	<brief_title>Cisplatin Gemcitabine Compared With Observation Treating Patients Who Have Undergone Surgery Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall , cause-specific , disease-free survival patient high-risk muscle-invasive transitional cell carcinoma bladder treat adjuvant cisplatin gemcitabine v observation radical cystectomy . - Compare dose intensity toxicity two different schedule cisplatin gemcitabine patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center disease status ( T2 [ G3 ] T3-4 [ G ] , N0-2 v T , N1-2 , M0 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients randomize 1 2 treatment regimen . - Regimen A : Patients receive cisplatin IV day 2 gemcitabine IV day 1 , 8 , 15 . - Regimen B : Patients receive cisplatin IV day 15 gemcitabine regimen A . Treatment regimens repeat every 28 day 4 course . - Arm II : Patients undergo observation follow cisplatin gemcitabine arm I relapse . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 700 patient ( 350 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder T2 ( G3 ) T34 ( G ) , N02 T , N12 , M0 No secondary localization Radical cystectomy ( without residual disease ) perform within 10 week prior study entry include : Men : Cystectomy removal prostate seminal vesicle include 1.5 cm urethra plus pelvic lymphadenectomy ( least 15 negative lymph node recommend define N0 ) Women : Cystectomy complete removal bladder , uterus , ovary , anterior wall vagina plus pelvic lymphadenectomy PATIENT CHARACTERISTICS : Age 18 74 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC least 3,500/mm^3 Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin less upper normal limit ( ULN ) GammaGT le ULN SGOT SGPT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal Creatinine great than1.25 time ULN Creatinine clearance least 60 mL/min Cardiovascular No congestive heart failure No angina pectoris No cardiac arrhythmia No uncontrolled arterial hypertension No history acute myocardial infarction within past year Other No serious concurrent illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy Palliative radiotherapy allow relapse symptomatic bone metastases Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>